Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) Meeting Abstract
| Authors: | Rischin, D.; Lim, A. M.; Schmults, C. D.; Khushalani, N. I.; Hughes, B. G.; Schadendorf, D.; Dunn, L. A.; Chang, A. L. S.; Hauschild, A.; Ulrich, C.; Eigentler, T.; Migden, M. R.; Pavlick, A. C.; Geiger, J.; Stankevich, E.; Li, S.; Lowy, I.; Fury, M. G.; Guminski, A. |
| Abstract Title: | Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz255.007 |
| Language: | English |
| ACCESSION: | WOS:000491295503363 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz255.007 |
| Notes: | Meeting Abstract: 1318P -- Appears on pages v536-v537 of the abstract book -- Source: Wos |
